The UK and US have signed a major trade agreement that will keep no tariffs on UK medicine exports being sold in the US market.
Key Provisions of the Accord
As part of the deal, the UK has committed to increase expenditure on drugs through the public health system. This commitment guarantees that tariffs on these vital exports will be held at nothing for a timeframe of three years.
This deal comes after previous statements to dramatically increase import taxes on branded pharmaceutical imports, with figures discussed as high as double the cost.
"This deal with the United Kingdom bolsters the global environment for innovative medicines and brings much-needed balance to American-British pharmaceutical trade," an announcement declared.
Trade Importance
Pharmaceuticals are one of the the United Kingdom's largest exports to the America, which is clearly the primary buyer for major British pharmaceutical firms.
Trade data indicate that in the 12 months leading up to September, the UK shipped pharmaceutical products valued at £11.1bn to the US. This amount accounted for 17.4% of total UK exports in that span.
"This deal safeguards work, stimulates investment and paves the way for the UK to establish itself as a worldwide center for medical research," a government official commented.
Key UK Commitments
The deal includes several key commitments from the United Kingdom:
- Revised Affordability Limit: The UK will raise the affordability limit at which it considers new treatments to be too expensive by a quarter.
- Increased NHS Spending: There is a target to increase overall public funding on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
- Payback Limit: The sum drug companies must pay back to the NHS to stay within budget will be restricted at fifteen percent. Previously, refunds were more than twenty percent.
Recent Tensions
The deal comes amid a ongoing tension between the sector and the ministers over spending levels and NHS adoption.
These tensions were exacerbated by arguments that US patients were charged a premium for the same drugs than people in the other developed nations.
In recent months, several major drug company projects in the UK have been paused or scrapped, while multi-billion-dollar funding commitments have been directed toward American operations.
The Science Minister publicly accepted that the NHS had to invest a greater share on medicines, noting that its budget allocation on drugs had declined as a percentage of its total funding over the last ten years.
